Comment by DrBenCarson

Cheap drugs have massive downward price pressure on alternatives.

The cynic in me thinks they are only going for Semaglutide because the patent expires in several places in 2026, tirzepatide has another ten years.

Or do both, and let them compete with each other for Medicare's business.